Kexing Biopharm's GB19 Injection Receives Clinical Trial Approval for Cutaneous Lupus Erythematosus

Stock News03-03

Kexing Biopharm Co., Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration. The NMPA has approved the clinical trial of the subsidiary's self-developed innovative drug "GB19 Injection," which targets BDCA2 (Blood Dendritic Cell Antigen 2), for the treatment of cutaneous lupus erythematosus (CLE). The approval of the clinical trial for this indication is not expected to have a significant impact on the company's recent financial condition or operating performance. As of the announcement date, the GB19 Injection has successively obtained NMPA approval to conduct clinical trials for both systemic lupus erythematosus and cutaneous lupus erythematosus indications. If the drug is successfully developed and commercialized in the future, it could provide a more diversified product offering to meet market demand, enriching the company's product portfolio and further enhancing its market competitiveness.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1152589531?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 19:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152589531","market":"nz","top_or_hot":-1,"title":"Kexing Biopharm's GB19 Injection Receives Clinical Trial Approval for Cutaneous Lupus Erythematosus","media":"Stock News","content":"<p>Kexing Biopharm Co., Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration. The NMPA has approved the clinical trial of the subsidiary's self-developed innovative drug \"GB19 Injection,\" which targets BDCA2 (Blood Dendritic Cell Antigen 2), for the treatment of cutaneous lupus erythematosus (CLE). The approval of the clinical trial for this indication is not expected to have a significant impact on the company's recent financial condition or operating performance. As of the announcement date, the GB19 Injection has successively obtained NMPA approval to conduct clinical trials for both systemic lupus erythematosus and cutaneous lupus erythematosus indications. If the drug is successfully developed and commercialized in the future, it could provide a more diversified product offering to meet market demand, enriching the company's product portfolio and further enhancing its market competitiveness.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kexing Biopharm's GB19 Injection Receives Clinical Trial Approval for Cutaneous Lupus Erythematosus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKexing Biopharm's GB19 Injection Receives Clinical Trial Approval for Cutaneous Lupus Erythematosus\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-03 19:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Kexing Biopharm Co., Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration. The NMPA has approved the clinical trial of the subsidiary's self-developed innovative drug \"GB19 Injection,\" which targets BDCA2 (Blood Dendritic Cell Antigen 2), for the treatment of cutaneous lupus erythematosus (CLE). The approval of the clinical trial for this indication is not expected to have a significant impact on the company's recent financial condition or operating performance. As of the announcement date, the GB19 Injection has successively obtained NMPA approval to conduct clinical trials for both systemic lupus erythematosus and cutaneous lupus erythematosus indications. If the drug is successfully developed and commercialized in the future, it could provide a more diversified product offering to meet market demand, enriching the company's product portfolio and further enhancing its market competitiveness.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688136","symbol_name":"科兴制药","start_time":0,"source_url":"","article_id":"1152589531","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152589531","pubTimestamp":1772536816,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Kexing Biopharm Co., Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice from the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688136":"科兴制药","BK0239":"医药制造"},"translate_title":"科兴生物GB19注射液获皮肤红斑狼疮临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688136":1},"content_text":"Kexing Biopharm Co., Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration. The NMPA has approved the clinical trial of the subsidiary's self-developed innovative drug \"GB19 Injection,\" which targets BDCA2 (Blood Dendritic Cell Antigen 2), for the treatment of cutaneous lupus erythematosus (CLE). The approval of the clinical trial for this indication is not expected to have a significant impact on the company's recent financial condition or operating performance. As of the announcement date, the GB19 Injection has successively obtained NMPA approval to conduct clinical trials for both systemic lupus erythematosus and cutaneous lupus erythematosus indications. If the drug is successfully developed and commercialized in the future, it could provide a more diversified product offering to meet market demand, enriching the company's product portfolio and further enhancing its market competitiveness.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1152589531","isCrawlerRequest":true}